Cabio Biotech (Wuhan) Co., Ltd.

SHSE:688089 Stock Report

Market Cap: CN¥3.2b

Cabio Biotech (Wuhan) Management

Management criteria checks 4/4

Cabio Biotech (Wuhan)'s CEO is Dewei Yi, appointed in Dec 2015, has a tenure of 9.08 years. directly owns 1.39% of the company’s shares, worth CN¥44.37M. The average tenure of the management team and the board of directors is 9.1 years and 6.1 years respectively.

Key information

Dewei Yi

Chief executive officer

CN¥1.1m

Total compensation

CEO salary percentagen/a
CEO tenure9.1yrs
CEO ownership1.4%
Management average tenure9.1yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings

Nov 04
We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings

Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Oct 28
Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

Oct 01
Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Aug 06
There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Jun 07
Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

May 06
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

May 03
Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Mar 21
The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

CEO

Dewei Yi (59 yo)

9.1yrs

Tenure

CN¥1,090,600

Compensation

Mr. Dewei Yi is Chairman and General Manager of CABIO Biotech(Wuhan) Co., Ltd., since December 2015. From December 1999 he has been the chairman of Wuhan Xiwang Biological Engineering Co., Ltd.; since Nove...

Leadership Team

NamePositionTenureCompensationOwnership
Dewei Yi
Chairman & GM9.1yrsCN¥1.09m1.39%
CN¥ 44.4m
Huabiao Wang
Financial Director & Director9.1yrsCN¥781.40k0.66%
CN¥ 21.1m
Huarong Yi
Deputy GM & Secretary of the Board of Directorsno dataCN¥640.10k0.089%
CN¥ 2.9m
Anfeng Geng
Deputy General Manager3.8yrsCN¥713.40k0.098%
CN¥ 3.2m
Zhiming Wang
Deputy General Manager3.1yrsCN¥862.90k0.14%
CN¥ 4.5m
Xiangyu Li
Deputy General Manager9.1yrsCN¥763.90k0.12%
CN¥ 3.9m
Tao Ma
Deputy General Manager9.1yrsCN¥640.90k0.093%
CN¥ 3.0m
Hao Xiong
Accounting Supervisorno datano datano data

9.1yrs

Average Tenure

48yo

Average Age

Experienced Management: 688089's management team is seasoned and experienced (9.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dewei Yi
Chairman & GM9.1yrsCN¥1.09m1.39%
CN¥ 44.4m
Huabiao Wang
Financial Director & Director9.1yrsCN¥781.40k0.66%
CN¥ 21.1m
Bin Du
Vice Chairman9.1yrsCN¥984.80k0.58%
CN¥ 18.6m
Yujun Wu
Employee Representative Supervisor9.1yrsno data0.018%
CN¥ 582.0k
Chunyu Zhang
Director3.1yrsno datano data
Xiangdong Chen
Independent Director3.1yrsCN¥80.00kno data
Qi Liu
Independent Director3.1yrsCN¥80.00kno data
Jing Chen
Supervisor3.1yrsno datano data

6.1yrs

Average Tenure

53.5yo

Average Age

Experienced Board: 688089's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 10:24
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cabio Biotech (Wuhan) Co., Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wendan WangChina International Capital Corporation Limited
Zhuonan XuChina International Capital Corporation Limited
Yifan DuCitic Securities Co., Ltd.